NEXEL - Statement about FLEXcyte technology
“The FLEXcyte brings another dimension to iPS-derived cardiomyocyte based assays. Measuring contractility in such a direct and easy way allows us to understand the cell functionality better and will help us in both our product development and safety pharmacology research.”
Choong-seong (Henry) Han DDS PhD
CEO, Founder, NEXEL Co., Ltd.